A Critical Appraisal of the Value of the Mouse Cancer Bioassay in Safety Assessment

Abstract

Substantial progress in understanding nongenotoxic or secondary mechanisms of tumorigenesis has been made over the past decade. However, the methods used in regulated studies for assessment of carcinogenic potential in chemicals in development have not evolved significantly. Based on the experience of over 30 yr of testing and the societal need to control costs, reevaluation of standard cancer rodent bioassay protocols is being done. Expert consensus after evaluating the results of full-scale rodent bioassays of both sexes in 2 species is that a reduced protocol is acceptable. After review of relevant data, it is our opinion that cancer hazard assessment in male and female rats only would be sufficient and that, in the future, mouse bioassays will not add significant value on a routine basis. We are unable to find an example of a mouse tumorigenic finding that predicts a confirmed or probable human response with negative findings in a rat bioassay. The savings realized by eliminating mouse testing from routine protocols would be substantial and better spent in expanding short-term studies to add to our understanding of chemical carcinogenesis.

References

Alden C. and Frith C. (1991). Urinary system. In: Handbook of Toxicologic Pathology, WM Haschek-Hock and CG Rosseaux (eds). Academic Press, London, pp. 315-385.

Davies T. and Monro A. (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. J. Am. Coll. Toxicol. 14: 90-107.

Haseman JK and Huff JE (1987). Species correlation in long-term carcinogenicity . Cancer Lett. 37: 125-132.

Huff J. , Cirvello J. , Haseman J. , and Bucher J. (1991). Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ. Health Perspec. 93: 247-270.

Infante PF (1993). Use of rodent carcinogenicity test results for determining potential cancer risk to humans. Environ. Health Perspec. 101(suppl. 5): 143-148.

Kew MC (1993). Cancer in the liver. Current Opinion in Gastroenterology 9: 429-434.

Lai DY (1992). Perspective on alternative carcinogenicity testing design: Possible use of reduced protocols, Mechanistic data and predictive techniques. Environ. Carcino. Ecotox. Rev. c10(1): 121-140.

Lai DY , Baetcke KP , Vu VT , Cotruvo JA , and Eustis SL (1994). Evaluation of reduced protocols for carcinogenicity testing of chemicals: Report of a Joint EPA/NIEHS Workshop. Reg. Toxicol. Pharmacol. 19: 183-201.

Monro A. (1993). How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to human? Adverse Drug React. Toxicol. Rev. 12: 5-34.

10.

Pitot HC and Dragan YP (1994). Chemical induction of hepatic neoplasia. In: The Liver Biology and Pathobiology, 3rd ed., IM Arias (ed.). Raven Press, Philadelphia, pp. 1467-1495.

11.

Purchase IFH (1980). Inter-species comparisons of carcinogenicity. Br. J. Cancer 41: 454-468.

12.

Rubin E. and Farber JL (1988). The liver and biliary. In: Pathology . MD Emuanel Rubin (ed). J. B. Lippincott, Philadelphia. pp. 722-807.

13.

Schach von Wittenau M. and Estes PC (1983). The redundancy of mouse carcinogenicity bioassays. Fund. Appl. Toxicol. 3: 631-639.

14.

Smith PF (1996). Third International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use-A toxicologist's perspective. Toxicol. Pathol . 4: 519-528.

15.

Swirsky Gold L. Bernstein L. Magaw R. and Slone T. (1989). Interspecies extrapolation in carcinogenesis: Prediction between rats and mice. Environ. Health Perspec. 81: 211-219.

16.

Takagi H. , Sharp R. , Takayama H. , Anver M. , Ward J. , and Merlino G. (1993). Collaboration between growth factors and diverse chemical carcinogens in hepatocarcinogenesis of transforming growth factor in transgenic mice. Cancer Res. 53: 4329-4336.

17.

Vainio H. , Coleman M. , and Wilbourn J. (1991). Carcinogenicity evaluations and ongoing studies: The IARC databases. Environ. Health Perspec. 96: 5-9.

18.

Vainio H. , Wilbourn JD , Sasco AJ , Partensky C. , Gaudin N. , Heseltine E. (1995). Identification of human carcinogenic risk in IARC monographs. Bull. Cancer 82: 339-348.